4D Molecular Therapeutics Inc Ordinary Shares FDMT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
-
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
-
Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm
-
4DMT Announces Presentations at Upcoming Retina Conferences
-
4DMT to Participate in the 2024 Cantor Global Healthcare Conference
-
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 24.24
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 201
Comparables
Valuation
|
Metric
|
FDMT
|
RNA
|
SLRN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.91 | 4.21 | 0.86 |
Price/Sales | 24.24 | 382.16 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FDMT
|
RNA
|
SLRN
|
|---|---|---|---|
Quick Ratio | 27.93 | 15.61 | 7.77 |
Current Ratio | 28.48 | 15.78 | 7.86 |
Interest Coverage | — | — | — |
Quick Ratio
FDMT
RNA
SLRN
Profitability
|
Metric
|
FDMT
|
RNA
|
SLRN
|
|---|---|---|---|
Return on Assets (Normalized) | −18.90% | −25.50% | −31.90% |
Return on Equity (Normalized) | −20.24% | −28.88% | −34.95% |
Return on Invested Capital (Normalized) | −24.42% | −33.01% | −40.49% |
Return on Assets
FDMT
RNA
SLRN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vqrljsjp | Vwzj | $516.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gchfwkwr | Chjgfd | $117.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Sxkzfjdkp | Hcxwh | $111.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qkhrgqvz | Tkmlq | $34.6 Bil | |||
| argenx SE ADR
ARGX
| Pjrftbcg | Kfcyb | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Bpnxbsgrs | Btyrq | $28.5 Bil | |||
| Moderna Inc
MRNA
| Dxkqsvxx | Vsfzv | $23.5 Bil | |||
| United Therapeutics Corp
UTHR
| Xlddtlscl | Hztzd | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Pvxxdsw | Wlfrqvd | $13.0 Bil | |||
| Incyte Corp
INCY
| Vqdsvdxy | Bdhjhg | $12.9 Bil |
United States